Tumor Mutation Burden as a Biomarker in Resected Non–Small-Cell Lung Cancer

2018295 citationsJournal Articlegreen Open Access

Authors

Siddhartha Devarakonda · Université Paris-Saclay

Federico Rotolo · Université Paris-Saclay

Ming‐Sound Tsao · Université Paris-Saclay

Irena Lanc · Université Paris-Saclay

Élisabeth Brambilla · Université Paris-Saclay

Ashiq Masood · Université Paris-Saclay

Ken A. Olaussen ·

Abstract

High nonsynonymous TMB was associated with a better prognosis in patients with resected NSCLC. In addition, the benefit of adjuvant chemotherapy on LCSS was more pronounced in patients with low nonsynonymous TMBs. Studies are warranted to confirm these findings.

Topics & Keywords

Lung Cancer Treatments and Mutations Lung Cancer Diagnosis and Treatment Cancer Genomics and Diagnostics

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 36, Issue 30, pp. 2995-3006

DOI: 10.1200/jco.2018.78.1963

Field-Weighted Citation Impact: 34.26